Medical Consequences of Drug Abuse and Infections Branch, National Institute on Drug Abuse, NIH, Bethesda, MD, USA.
, 24924 McNair Place, Aldie, VA, 20105, USA.
J Neuroimmune Pharmacol. 2021 Dec;16(4):718-721. doi: 10.1007/s11481-021-10013-8. Epub 2021 Oct 16.
COVID-19 epidemic has resulted in devastating mortality and morbidity consisting of socioeconomic and health effects that have included respiratory/pulmonary, cardiovascular, mental health and neurological consequences such as anxiety, depression, and substance use. Several effective vaccines have been developed and extensive efforts are underway to develop therapeutics to treat COVID-19. Cannabis and/or its product-cannabidiol (CBD) are being advertised for the treatment of COVID-19 associated mental/neurological complications and substance use disorders. However, research reviewed shows that there is insufficient data from clinical studies to support the use of cannabis or CBD for the treatment of COVID-19 associated mental health and neurological complications. Additional basic and clinical research is suggested to develop cannabis or cannabidiol for the treatment of mental health problems associated with coronavirus infection and or substance use disorders. In the meantime, it is important that the addiction physician/psychiatrist must caution while prescribing or recommending cannabis or CBD for treating such clinical indications. Research shows that currently there is no clinical evidence to support the use of cannabis or any of its compounds including CBD for treating any of the neuropsychiatric complications of COVID-19. Thus, it is important that the addiction physicians/psychiatrists caution their patients from using cannabis or cannabis products for treating any such complications.
COVID-19 疫情导致了毁灭性的死亡率和发病率，包括对社会经济和健康的影响，其中包括呼吸道/肺部、心血管、心理健康和神经后果，如焦虑、抑郁和物质使用。已经开发出几种有效的疫苗，并且正在进行广泛的努力开发治疗 COVID-19 的疗法。大麻及其产品大麻二酚 (CBD) 被宣传用于治疗与 COVID-19 相关的精神/神经并发症和物质使用障碍。然而，审查的研究表明，没有足够的临床研究数据支持使用大麻或 CBD 治疗与 COVID-19 相关的心理健康和神经并发症。建议进行更多的基础和临床研究，以开发大麻或大麻二酚治疗与冠状病毒感染和/或物质使用障碍相关的心理健康问题。同时，重要的是，成瘾医生/精神科医生在开处方或推荐大麻或 CBD 治疗此类临床病症时必须谨慎。研究表明，目前没有临床证据支持使用大麻或其任何化合物（包括 CBD）治疗 COVID-19 的任何神经精神并发症。因此，重要的是，成瘾医生/精神科医生告诫他们的患者不要使用大麻或大麻制品治疗任何此类并发症。
